MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net
$5,493,086
Proceeds from issuance of
pre-funded warrants, net
$3,822,894
Proceeds from issuance of
common stock under...
$2,540,931
Proceeds from issuance of
debt
$150,000
Net cash provided by
financing activities
$10,669,509
Canceled cashflow
$1,337,402
Net increase
(decrease) in cash and cash...
-$2,722,108
Canceled cashflow
$10,669,509
Impairment of long-lived
asset
$1,500,000
Depreciation and accretion
$1,041,771
Stock-based compensation
$768,623
Accounts receivable
-$550,026
Change in fair value of
investment
-$273,422
Loss on sale of put
shares
-$263,974
Commitment fee
$150,000
Prepaid expenses and
other assets
-$141,989
Revenues
$54,232
Issuance costs for common
stock, pre-funded...
$1,209,779
Debt repayment
-$127,623
Net cash used in
operating activities
-$13,391,617
Canceled cashflow
$4,689,805
Net revenues
$10,846
Canceled cashflow
$43,386
Net loss
-$7,959,709
Gain on
extinguishment of liability
$5,461,046
Canceled cashflow
$10,846
Accounts payable and
other liabilities
-$3,473,706
Change in fair value of
contingent liability
$1,055,826
Loss on conversion of
debt with related...
$131,135
Other segment items
-$4,768,388
Cost of revenues
$43,386
Total operating
expenses
$7,970,555
Canceled cashflow
$4,768,388
General and
administrative
$7,296,059
Research and development
expenses
$5,442,884
Back
Back
Cash Flow
source: myfinsight.com
HCW Biologics Inc. (HCWB)
HCW Biologics Inc. (HCWB)